Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Wilder, Julius M., Jia Yao, Makarushka Christina, Donna Evon, Michael W. Fried, Susanna Naggie, Andrew J. Muir, and Rae Jean Proeschold-Bell. “ASSOCIATIONS OF ALCOHOL CONSUMPTION MOTIVES WITH DEPRESSION AND PAIN AMONG INDIVIDUALS WITH HEPATITIS C.” In Gastroenterology, 154:S1121–22. W B SAUNDERS CO-ELSEVIER INC, 2018.

Scholars@Duke

Okeke, Nwora Lance, Damian M. Craig, Michael J. Muehlbauer, Olga Ilkayeva, Meredith E. Clement, Susanna Naggie, and Svati H. Shah. “Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study..” Metabolomics 14, no. 3 (March 2018). https://doi.org/10.1007/s11306-018-1318-z.

PMID
30760970
Full Text

Clement, Meredith E., Li Lin, Ann Marie Navar, Nwora Lance Okeke, Susanna Naggie, and Pamela S. Douglas. “Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome..” Medicine (Baltimore) 97, no. 6 (February 2018). https://doi.org/10.1097/MD.0000000000009849.

PMID
29419696
Full Text

Collins, Lauren F., Austin Chan, Jiayin Zheng, Shein-Chung Chow, Julius M. Wilder, Andrew J. Muir, and Susanna Naggie. “Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection..” Open Forum Infect Dis 5, no. 1 (January 2018). https://doi.org/10.1093/ofid/ofx264.

PMID
29308413
Full Text

Morgan, Jake R., Arthur Y. Kim, Susanna Naggie, and Benjamin P. Linas. “The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets..” Open Forum Infect Dis 5, no. 1 (January 2018). https://doi.org/10.1093/ofid/ofx267.

PMID
29354660
Full Text

Lok, Anna S., Raymond T. Chung, Hugo E. Vargas, Arthur Y. Kim, Susanna Naggie, and William G. Powderly. “Benefits of Direct-Acting Antivirals for Hepatitis C..” Ann Intern Med 167, no. 11 (December 5, 2017): 812–13. https://doi.org/10.7326/M17-1876.

PMID
29049502
Full Text

Zuckerman, Autumn, Cody A. Chastain, and Susanna Naggie. “Retreatment Options Following HCV Direct Acting Antiviral Failure..” Curr Treat Options Infect Dis 9, no. 4 (December 2017): 389–402. https://doi.org/10.1007/s40506-017-0136-6.

PMID
29242710
Full Text

Powderly, William G., Susanna Naggie, Arthur Y. Kim, Hugo E. Vargas, Raymond T. Chung, and Anna S. Lok. “IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C..” Clin Infect Dis 65, no. 11 (November 13, 2017): 1773–75. https://doi.org/10.1093/cid/cix620.

PMID
29020156
Full Text

Babich, Tanya, Oren Zusman, Michal Elbaz, Haim Ben-Zvi, Mical Paul, Leonard Leibovici, and Tomer Avni. “Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary Tract Infection: Prospective Cohort Study.” Clinical Infectious Diseases 65, no. 11 (November 13, 2017): 1799–1805. https://doi.org/10.1093/cid/cix680.

Full Text

Naggie, Susanna, Daniel S. Fierer, Michael Hughes, Arthur Y. Kim, Anne Luetkemeyer, Vincent Vu, Jhoanna Roa, et al. “100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals).” In Hepatology, 66:113A-113A. WILEY, 2017.

Scholars@Duke

Pages